The Ministry of Health, Labor and Welfare (MHLW; Korosho) issued on November 25 a director-general notification to prefectural governments informing them of the two-year extension of the reexamination period for Dainippon Sumitomo Pharma’s (DSP) antipsychotic agent Lonasen Tablets 2 mg,…
To read the full story
REGULATORY
- TNF Inhibitors, Cancer Drugs Flagged in PMDA Risk Review
March 30, 2026
- Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
- MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
March 27, 2026
- AMED Warns Projects without Japan Return May Miss Startup Funding
March 26, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





